Research programme: IMPDH inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: IMPDH inhibitors - Bristol-Myers Squibb

Alternative Names: BMS-566419

Latest Information Update: 01 Mar 2011

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Acridines; Piperazines
  • Mechanism of Action Inosine monophosphate dehydrogenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Rheumatoid arthritis; Transplant rejection

Most Recent Events

  • 01 Mar 2011 No development reported - Preclinical for Transplant rejection in USA (unspecified route)
  • 01 Mar 2011 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)
  • 28 Aug 2007 Prelinical data added to the, pharmacokinetics, adverse events and Rheumatic Disease pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top